628 related articles for article (PubMed ID: 16397231)
1. Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells.
Roccaro AM; Hideshima T; Raje N; Kumar S; Ishitsuka K; Yasui H; Shiraishi N; Ribatti D; Nico B; Vacca A; Dammacco F; Richardson PG; Anderson KC
Cancer Res; 2006 Jan; 66(1):184-91. PubMed ID: 16397231
[TBL] [Abstract][Full Text] [Related]
2. Caveolin-1 is required for vascular endothelial growth factor-triggered multiple myeloma cell migration and is targeted by bortezomib.
Podar K; Shringarpure R; Tai YT; Simoncini M; Sattler M; Ishitsuka K; Richardson PG; Hideshima T; Chauhan D; Anderson KC
Cancer Res; 2004 Oct; 64(20):7500-6. PubMed ID: 15492276
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma.
Voorhees PM; Chen Q; Kuhn DJ; Small GW; Hunsucker SA; Strader JS; Corringham RE; Zaki MH; Nemeth JA; Orlowski RZ
Clin Cancer Res; 2007 Nov; 13(21):6469-78. PubMed ID: 17975159
[TBL] [Abstract][Full Text] [Related]
4. Tetraiodothyroacetic acid, a small molecule integrin ligand, blocks angiogenesis induced by vascular endothelial growth factor and basic fibroblast growth factor.
Mousa SA; Bergh JJ; Dier E; Rebbaa A; O'Connor LJ; Yalcin M; Aljada A; Dyskin E; Davis FB; Lin HY; Davis PJ
Angiogenesis; 2008; 11(2):183-90. PubMed ID: 18080776
[TBL] [Abstract][Full Text] [Related]
5. Growth-regulated oncogene is pivotal in thrombin-induced angiogenesis.
Caunt M; Hu L; Tang T; Brooks PC; Ibrahim S; Karpatkin S
Cancer Res; 2006 Apr; 66(8):4125-32. PubMed ID: 16618733
[TBL] [Abstract][Full Text] [Related]
6. Endothelial cell response to lactate: implication of PAR modification of VEGF.
Kumar VB; Viji RI; Kiran MS; Sudhakaran PR
J Cell Physiol; 2007 May; 211(2):477-85. PubMed ID: 17167776
[TBL] [Abstract][Full Text] [Related]
7. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model.
LeBlanc R; Catley LP; Hideshima T; Lentzsch S; Mitsiades CS; Mitsiades N; Neuberg D; Goloubeva O; Pien CS; Adams J; Gupta D; Richardson PG; Munshi NC; Anderson KC
Cancer Res; 2002 Sep; 62(17):4996-5000. PubMed ID: 12208752
[TBL] [Abstract][Full Text] [Related]
8. The proteasome inhibitor bortezomib induces apoptosis in human retinoblastoma cell lines in vitro.
Poulaki V; Mitsiades CS; Kotoula V; Negri J; McMillin D; Miller JW; Mitsiades N
Invest Ophthalmol Vis Sci; 2007 Oct; 48(10):4706-19. PubMed ID: 17898295
[TBL] [Abstract][Full Text] [Related]
9. MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo.
Hideshima T; Neri P; Tassone P; Yasui H; Ishitsuka K; Raje N; Chauhan D; Podar K; Mitsiades C; Dang L; Munshi N; Richardson P; Schenkein D; Anderson KC
Clin Cancer Res; 2006 Oct; 12(19):5887-94. PubMed ID: 17020997
[TBL] [Abstract][Full Text] [Related]
10. Bortezomib and zoledronic acid on angiogenic and vasculogenic activities of bone marrow macrophages in patients with multiple myeloma.
Moschetta M; Di Pietro G; Ria R; Gnoni A; Mangialardi G; Guarini A; Ditonno P; Musto P; D'Auria F; Ricciardi MR; Dammacco F; Ribatti D; Vacca A
Eur J Cancer; 2010 Jan; 46(2):420-9. PubMed ID: 19914061
[TBL] [Abstract][Full Text] [Related]
11. Bortezomib inhibits the angiogenesis mediated by mesenchymal stem cells.
Wang X; Zhang Z; Yao C
Cancer Invest; 2012 Nov; 30(9):657-62. PubMed ID: 23013101
[TBL] [Abstract][Full Text] [Related]
12. HIF-1α of bone marrow endothelial cells implies relapse and drug resistance in patients with multiple myeloma and may act as a therapeutic target.
Ria R; Catacchio I; Berardi S; De Luisi A; Caivano A; Piccoli C; Ruggieri V; Frassanito MA; Ribatti D; Nico B; Annese T; Ruggieri S; Guarini A; Minoia C; Ditonno P; Angelucci E; Derudas D; Moschetta M; Dammacco F; Vacca A
Clin Cancer Res; 2014 Feb; 20(4):847-58. PubMed ID: 24297864
[TBL] [Abstract][Full Text] [Related]
13. Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma.
Vacca A; Scavelli C; Montefusco V; Di Pietro G; Neri A; Mattioli M; Bicciato S; Nico B; Ribatti D; Dammacco F; Corradini P
J Clin Oncol; 2005 Aug; 23(23):5334-46. PubMed ID: 15939924
[TBL] [Abstract][Full Text] [Related]
14. Nobiletin, a citrus polymethoxyflavonoid, suppresses multiple angiogenesis-related endothelial cell functions and angiogenesis in vivo.
Kunimasa K; Ikekita M; Sato M; Ohta T; Yamori Y; Ikeda M; Kuranuki S; Oikawa T
Cancer Sci; 2010 Nov; 101(11):2462-9. PubMed ID: 20670297
[TBL] [Abstract][Full Text] [Related]
15. Grape seed proanthocyanidins inhibit angiogenesis via the downregulation of both vascular endothelial growth factor and angiopoietin signaling.
Huang S; Yang N; Liu Y; Hu L; Zhao J; Gao J; Li Y; Li C; Zhang X; Huang T
Nutr Res; 2012 Jul; 32(7):530-6. PubMed ID: 22901561
[TBL] [Abstract][Full Text] [Related]
16. Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma.
Hideshima T; Chauhan D; Hayashi T; Akiyama M; Mitsiades N; Mitsiades C; Podar K; Munshi NC; Richardson PG; Anderson KC
Oncogene; 2003 Nov; 22(52):8386-93. PubMed ID: 14627979
[TBL] [Abstract][Full Text] [Related]
17. Lentiviral shRNA silencing of BDNF inhibits in vivo multiple myeloma growth and angiogenesis via down-regulated stroma-derived VEGF expression in the bone marrow milieu.
Zhang L; Hu Y; Sun CY; Li J; Guo T; Huang J; Chu ZB
Cancer Sci; 2010 May; 101(5):1117-24. PubMed ID: 20331634
[TBL] [Abstract][Full Text] [Related]
18. The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment.
Lin B; Podar K; Gupta D; Tai YT; Li S; Weller E; Hideshima T; Lentzsch S; Davies F; Li C; Weisberg E; Schlossman RL; Richardson PG; Griffin JD; Wood J; Munshi NC; Anderson KC
Cancer Res; 2002 Sep; 62(17):5019-26. PubMed ID: 12208756
[TBL] [Abstract][Full Text] [Related]
19. Pulse treatment with the proteasome inhibitor bortezomib inhibits osteoclast resorptive activity in clinically relevant conditions.
Boissy P; Andersen TL; Lund T; Kupisiewicz K; Plesner T; Delaissé JM
Leuk Res; 2008 Nov; 32(11):1661-8. PubMed ID: 18394701
[TBL] [Abstract][Full Text] [Related]
20. Bortezomib, dexamethasone, and fibroblast growth factor receptor 3-specific tyrosine kinase inhibitor in t(4;14) myeloma.
Bisping G; Wenning D; Kropff M; Gustavus D; Müller-Tidow C; Stelljes M; Munzert G; Hilberg F; Roth GJ; Stefanic M; Volpert S; Mesters RM; Berdel WE; Kienast J
Clin Cancer Res; 2009 Jan; 15(2):520-31. PubMed ID: 19147757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
